In contrast to breast cancer (where almost no GLCE upregulation was observed), prostate pathological tissues were characterized by a predominant increase in GLCE expression in 49% of the BPH tissues and a decrease in GLCE expression in 53% of the prostate tumor tissues. This evidence concerns the gene GLCE and breast cancer.